Enovis Corp

Health Care
Industrial Specialties
www.enovis.com

Earnings Score
Moat Score
Safety Score

Market Cap $1.88B
PE -2
Debt $1.36B
Cash $48.17M
EV $3.20B
FCF -$67.21M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$825.49M
EBIT	-$775.72M
ROE	-32%
ROA	-16%
FCF	-$67.21M
Equity	$2.56B
Growth Stability	-10K%
PE	-2.28
PEG	9.78
PB	0.73
P/FCF	-27.98
P/S	0.89
Price/Cash	0.03
Debt/Equity	0.53
Debt/FCF	-20.28
Net Margins	-39%
Gross Margins	56%
Op. Margins	-37%
Earnings CAGR	-2%
Sales Growth YoY	23%
Sales Growth QoQ	11%
Sales CAGR	-9%
FCF CAGR	-2%
Equity CAGR	0%
Earnings Stability	0.05
Earnings Growth YoY	-24K%

Earnings Growth QoQ	2K%
Earnings CAGR 5Y	-0%
Sales CAGR 5Y	-16%
FCF CAGR 5Y	-5%
Equity CAGR 5Y	-5%
Earnings CAGR 3Y	-11%
Sales CAGR 3Y	-11%
Equity CAGR 3Y	-10%
Market Cap	$1.88B
Revenue	$2.11B
Assets	$4.72B
Total Debt	$1.36B
Cash	$48.17M
Shares Outstanding	55.28M
EV	3.2B
Earnings Score	6%
Moat Score	2%
Safety Score	38%
Final Score	15%
Working Capital	617.45M
Current Ratio	2.17
Gross Profit	$1.18B
Shares Growth 3y	1%
Equity Growth QoQ	-23%
Equity Growth YoY	-25%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates in two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity solutions. It also provides Novastep, a minimally invasive surgery (MIS) foot and ankle solutions.

SEC Filings

Direct access to Enovis Corp (ENOV) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 27
- 10-Q Jun 28
- 10-Q Mar 29
2023
- 10-K Dec 31
- 10-Q Sep 29
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jul 01
- 10-Q Apr 01

Sector Comparison

How does Enovis Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Enovis Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -2%

Stability 5%

loading chart...

Enovis Corp Discounted Cash Flow

Fully customizable DCF calculator online for Enovis Corp.

Years

Calculation mode

= -$583M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$67M	-$66M	-$64M	-$63M	-$62M	-$60M	-$59M	-$58M	-$57M	-$55M	-$54M	-$542M
DCF		-$60M	-$53M	-$47M	-$42M	-$37M	-$33M	-$30M	-$26M	-$23M	-$21M	-$209M
Value	-$583M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	4%	4%	-2%	4%	-16%	1%	2%	-1%	-2%	-39%	-39%
ROA	-	4%	0%	4%	3%	2%	3%	-0%	-1%	-16%	-16%
ROE	-	4%	-2%	4%	-15%	1%	2%	-0%	-1%	-32%	-32%

Bad Net Margins (-39.17%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	7.1	7.17	7.73	425.02	12.15	8.35	-2.97	37.6	-20.28	-20.28
Debt over Equity	0.44	0.42	0.29	0.35	0.68	0.63	0.45	0.14	0.14	0.53	0.53
Growth Stability	-	-	-	100%	-810%	-	-	-	-99%	-10K%	-10K%

Good Debt/FCF ratio (-20.28)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.53)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-10K%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-8%	-10%	11%	-9%	-8%	26%	-59%	9%	23%	-16%
Earnings YoY growth	-	-24%	-157%	-292%	-476%	-108%	68%	-119%	150%	2K%	-0%
Equity YoY growth	-	-5%	20%	-7%	0%	3%	30%	-26%	-1%	-25%	-5%
FCF YoY growth	-	-21%	-18%	4%	-96%	3K%	35%	-164%	-108%	-627%	-5%